Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer – March 2022
The COVID-19 clinical and commercial analyzer is an interactive excel-based tool that scores leading pipeline-stage vaccines and therapeutics on a range of clinical and commercial parameters based on available clinical data.
Which are the key pipeline stage therapeutics in the COVID-19 clinical and commercial analyzer market?
The key pipeline stage therapeutics in the COVID-19 clinical and commercial analyzer market are remdesivir, dexamethasone, favipiravir, sotrovimab, tocilizumab, Paxlovid (nirmatrelvir + ritonavir), bebtelovimab, evusheld (tixagevimab + cilgavimab), molnupiravir, baricitinib, casirivimab + imdevimab, bamlanivimab + etesevimab, convalescent plasma, regdanvimab, sarilumab, eculizumab, chloroquine/hydroxychloroquine, SNG001, Octagam, leronlimab, lenzilumab, bamlanivimab, aviptadil, opaganib, and ensovibep.
COVID-19 clinical and commercial analyzer market, by pipeline stage therapeutics
For more pipeline stage therapeutic insights, download a free sample
Which are the key pipeline stage vaccines in the COVID-19 clinical and commercial analyzer market?
The key pipeline stage vaccines in the COVID-19 clinical and commercial analyzer market are Comirnaty (BNT162b2), BBIBP-CorV, Spikevax (mRNA-1273), Sputnik V, EpiVacCorona, AZD1222 (ChAdOx1), NVX-CoV2373, Covaxin (BBV152), Ad5-nCoV, CoronaVac, Ad26COV2.S, ZF-2001, VLA-2001, SCB-2019, MT-2766, INO-4800, SP-0253, ARCT-021, VXA-CoV2-1, CVnCoV, V-590, and V-591.
COVID-19 clinical and commercial analyzer market, by pipeline stage vaccines
For more pipeline stage vaccine insights, download a free sample
Who are the key players in the COVID-19 clinical and commercial analyzer market?
The key players in the COVID-19 clinical and commercial analyzer market are Inovio, Moderna, Regeneron, Novavax, Merck, Pfizer, Sanofi, GSK, Gilead, Chugai, Roche, AstraZeneca, Johnson & Johnson, Lilly.
Market report scope
| Key pipeline stage therapeutics | remdesivir, dexamethasone, favipiravir, sotrovimab, tocilizumab, Paxlovid (nirmatrelvir + ritonavir), bebtelovimab, evusheld (tixagevimab + cilgavimab), molnupiravir, baricitinib, casirivimab + imdevimab, bamlanivimab + etesevimab, convalescent plasma, regdanvimab, sarilumab, eculizumab, chloroquine/hydroxychloroquine, SNG001, Octagam, leronlimab, lenzilumab, bamlanivimab, aviptadil, opaganib, and ensovibep |
| Key pipeline stage vaccines | Comirnaty (BNT162b2), BBIBP-CorV, Spikevax (mRNA-1273), Sputnik V, EpiVacCorona, AZD1222 (ChAdOx1), NVX-CoV2373, Covaxin (BBV152), Ad5-nCoV, CoronaVac, Ad26COV2.S, ZF-2001, VLA-2001, SCB-2019, MT-2766, INO-4800, SP-0253, ARCT-021, VXA-CoV2-1, CVnCoV, V-590, and V-591 |
| Key companies | Inovio, Moderna, Regeneron, Novavax, Merck, Pfizer, Sanofi, GSK, Gilead, Chugai, Roche, AstraZeneca, Johnson & Johnson, Lilly |
Scope
This analyzer includes:
- Catalyst: Description of the most recent events impacting the COVID-19 R&D competitive landscape that are accounted for in the analysis
- Scope of Coverage and Methodology: Discussion of product inclusion criteria and outline of rationale and assumptions
- Clinical and Commercial Analyzer: Each asset is scored on a set of characteristics that will determine their post-launch success, including clinical features such as efficacy, safety, and dosing regimen and commercial attributes such as price, company reputation, and marketing and sales force strength
- Competitive Assessment: Visual representation of the results of the analyzer, depicting how the leading candidates compete
- Product Dashboard: Compilation of all key product features, plus a proprietary SWOT analysis of each product
- Clinical Data Summary: Listing of published clinical data for all products included in the analysis
Key Highlights
Competitive Assessment: Visual representation of the results of the analyzer, depicting how the leading candidates compete.
Product Dashboard: Compilation of all key product features, plus a proprietary SWOT analysis of each product.
Clinical Data Summary: Listing of published clinical data for all products included in the analysis.
Reasons to Buy
- With the constantly evolving COVID-19 outbreak, players need rapidly updated and detailed information on the potential for success for emerging vaccines and therapies. GlobalData’s COVID-19 Clinical and Commercial Analyzer will allow clients to:
- View scoring of assets which will impact their success in this dynamic field, with characteristics scored including clinical features such as safety and efficacy, and commercial features such as price and company reputation and marketing capabilities.
- Two important features of this are that the scores are easily visualized in a chart clearly depicting where different assets stand in the field. Further, the scoring sheet is live, meaning that clients can change scoring parameters based on their individual needs and preferences.
- Access to dashboards detailing out basic information for these agents such as mechanism of action, as well as GlobalData’s take on these assets, including SWOT analyses, with further linkage to summaries of available published clinical data for assets.
Key Players
Table of Contents
Frequently Asked Questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
GDPR + CCPA Compliant
Personal and transaction information are kept safe from unauthorised use.
Recently Viewed Reports
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.